Premium
Effects of Octreotide on Lipoproteins and Endothelial Function in Type 1 (Insulin‐dependent) Diabetic Patients
Author(s) -
Nørgaard K.,
Snorgaard O.,
Jensen T.,
Kirkegaard C.
Publication year - 1990
Publication title -
diabetic medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.474
H-Index - 145
eISSN - 1464-5491
pISSN - 0742-3071
DOI - 10.1111/j.1464-5491.1990.tb01327.x
Subject(s) - medicine , endocrinology , octreotide , von willebrand factor , somatostatin , fibrinogen , insulin , endothelial dysfunction , diabetes mellitus , acromegaly , microalbuminuria , hormone , platelet , growth hormone
Hypersecretion of growth hormone (GH) is a characteristic feature of Type 1 diabetic patients. In healthy subjects growth hormone is able to induce an increase in endothelial cell proteins such as fibrinogen and von Willebrand factor. Plasma concentrations of such proteins, which are markers of cardiovascular risk, are elevated in diabetic patients with microalbuminuria, suggesting endothelial cell dysfunction. In a randomized prospective study we therefore evaluated the possible effects of 1 year's treatment with a somatostatin analogue, octreotide, on lipoproteins and on endothelial function in Type 1 diabetes mellitus. Seven patients were allocated to treatment with a continuous subcutaneous infusion of 400 μg octreotide per day. Seven patients served as a control group. During treatment a decrease in plasma LDL‐cholesterol (2.62 (2.17–3.11) (median (range)) vs 2.00 (1.89–2.96) mmol l −1 , p < 0.05) and serum apolipoprotein A‐I (1.47 (1.25–1.60) vs 1.23 (1.13–1.90) g l −1 , p < 0.05) was observed in the treated group. Furthermore a probable reduction during treatment in plasma concentrations of von Willebrand factor (1.72 (0.84–3.04) vs 1.24 (0.94–1.82) U ml −1 , p = 0.08) and fibrinogen (11.3 (7.3–25.3) vs 8.1 (7.5–11.8) μmol l −1 , p = 0.06) was found, and after withdrawal of treatment an increase towards the initial levels was seen. The platelet count declined (326 (301–612) vs 217 (206–400) × 10 9 l −1 , p < 0.01) during octreotide treatment and remained depressed 2 months after withdrawal.